Abstract
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin®), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.
Key Words: HER2 • breast cancer • Herceptin®
Full Text
The Full Text of this article is available as a PDF (102.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Press M. F., Hung G., Godolphin W., Slamon D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994 May 15;54(10):2771–2777. [PubMed] [Google Scholar]
- Walker R. A. The significance of histological determination of HER-2 status in breast cancer. Breast. 2000 Jun;9(3):130–133. doi: 10.1054/brst.2000.0167. [DOI] [PubMed] [Google Scholar]
- Wang S., Saboorian M. H., Frenkel E., Hynan L., Gokaslan S. T., Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000 May;53(5):374–381. doi: 10.1136/jcp.53.5.374. [DOI] [PMC free article] [PubMed] [Google Scholar]